Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Up - Still a Buy?

Key Points

• Telix Pharmaceuticals shares experienced a significant gap up, opening at $9.51 compared to the previous close of $9.16, with trading occurring at approximately $9.75.
• Analysts maintain a generally positive outlook, with five analysts rating the stock as a "Buy" and one as "Hold," resulting in a consensus price target of $21.50.
• Institutional investors have recently increased their positions in Telix, with new acquisitions totaling around $4 million across several firms in the first and second quarters.

Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report)'s share price gapped up prior to trading on Friday . The stock had previously closed at $9.16, but opened at $9.51. Telix Pharmaceuticals shares last traded at $9.75, with a volume of 110,387 shares trading hands.

Wall Street Analyst Weigh In

TLX has been the subject of several research reports. Citigroup began coverage on Telix Pharmaceuticals in a research report on Thursday. They set a "buy" rating and a $22.00 price target for the company. William Blair reissued an "outperform" rating on shares of Telix Pharmaceuticals in a research report on Wednesday, July 9th. HC Wainwright reduced their price target on Telix Pharmaceuticals from $23.00 to $20.00 and set a "buy" rating for the company in a research report on Wednesday, September 10th. Wedbush reiterated an "outperform" rating and issued a $22.00 target price on shares of Telix Pharmaceuticals in a report on Thursday, August 28th. Finally, JPMorgan Chase & Co. reissued a "neutral" rating on shares of Telix Pharmaceuticals in a research report on Thursday, August 28th. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $21.50.

Telix Pharmaceuticals Stock Up 9.0%

The business has a fifty day moving average price of $11.88 and a 200 day moving average price of $15.10. The company has a current ratio of 2.78, a quick ratio of 2.66 and a debt-to-equity ratio of 0.99.

Hedge Funds Weigh In On Telix Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Private Advisor Group LLC purchased a new position in shares of Telix Pharmaceuticals in the 1st quarter worth about $170,000. IHT Wealth Management LLC purchased a new position in shares of Telix Pharmaceuticals in the second quarter worth about $213,000. Blair William & Co. IL acquired a new position in shares of Telix Pharmaceuticals during the 2nd quarter worth approximately $217,000. Vanguard Personalized Indexing Management LLC purchased a new stake in Telix Pharmaceuticals in the 2nd quarter valued at $297,000. Finally, ABC Arbitrage SA acquired a new stake in shares of Telix Pharmaceuticals in the first quarter valued at $451,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.